Atreca Revenue and Competitors

License our Company Data API

$222.9M

Total Funding

Estimated Revenue & Valuation

Atreca's estimated annual revenue is currently $25.3M per year.(i)
Atreca received $125.0M in venture funding in September 2018.
Atreca's estimated revenue per employee is $290,402
Atreca's total funding is $222.9M.
Atreca's current valuation is $76.7M. (January 2022)

Employee Data

Atreca has 87 Employees.(i)
Atreca grew their employee count by -17% last year.

Atreca's People

Name	Title	Email/Phone
1 Drew Wilhite	VP Human Resources	Reveal Email/Phone
2 Traci Ropp	VP, Intellectual Property	Reveal Email/Phone
3 Paulette Dillon	SVP Corporate Development	Reveal Email/Phone
4 Mark Camarena	VP Corporate Services	Reveal Email/Phone
5 Rick Ruiz	VP Finance	Reveal Email/Phone
6 Wayne Volkmuth	SVP Informatics & IT	Reveal Email/Phone
7 Shaun Lippow	VP, Drug Discovery & Protein Engineering	Reveal Email/Phone
8 Kate Williams	Head Business Development, Alliance & Portfolio Management	Reveal Email/Phone
9 Andrew Swinnerton	Director IT	Reveal Email/Phone
10 Jae Jung	Director Technical Accounting and SEC Reporting	Reveal Email/Phone

Atreca Competitors & AlternativesAdd Company

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 DiaCarta	$4.4M	57	-8%	$53M	N/A
#2 Mission Bio	$21.2M	137	-26%	$110M	N/A
#3 Quadrants Scien...	$0.9M	6	0%	N/A	N/A
#4 Calcilytix Ther...	$2.3M	15	15%	N/A	N/A
#5 Ravata Solution...	$1.6M	10	-17%	N/A	N/A
#6 Range Biotechno...	$0.7M	9	50%	N/A	N/A
#7 Mission Barns	$11.5M	74	-12%	N/A	N/A
#8 Geron Corporati...	$0.4M	275	10%	$236.7M	N/A
#9 Mindstrong	$4M	51	-74%	$160M	N/A
#10 CalciMedica	$2.3M	15	15%	N/A	N/A

Add Company

Show More Biotech Companies

What Is Atreca?

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture (IRC) technology, Atreca has an unparalleled insight into how cancer patients immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today's patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health. If you are interested in becoming part of the Atreca team, our open positions can be found at: http://www.atreca.com/careers/

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$222.9M

Total Funding

Number of Employees

$25.3M

Revenue (est)

-17%

Employee Growth %

$76.7M

Valuation

N/A

Accelerator

Atreca News

2022-04-19 - Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. (NASDAQ:BCEL) is a speculative biotech that should be on everyone's radar. That's because it has shown some preliminary...

2022-04-17 - Stealth BioTherapeutics (NASDAQ:MITO) & Atreca (NASDAQ ...

Stealth BioTherapeutics (NASDAQ:MITO) & Atreca (NASDAQ:BCEL) Head-To-Head Analysis. Posted by admin on Apr 18th, 2022.

2022-03-30 - Atreca Announces Expansion of Preclinical Pipeline

Atreca is a clinical-stage biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated...

2018-09-16 - Atreca Raises $125M in Series C Funding

Atreca, Inc., a Redwood City, Calif.-based biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, closed a $125m Series C financing. The round was led by an existing investor, which is un unnamed U.S.-based, healthcare-focused ...

2017-08-20 - Wellington Management Leads $35M Series B for Atreca

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced the completion of its Series B round of financing with a total investment of $35 million. The financing was ...